血腫:世界の治験レビュー(2017年下半期版)

GlobalDataが発行した調査報告書(GDHC4551CTIDB)
◆英語タイトル:Hematoma Global Clinical Trials Review, H2, 2017
◆商品コード:GDHC4551CTIDB
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年9月1日
◆ページ数:49
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD5,000 ⇒換算¥565,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD7,500 ⇒換算¥847,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、世界における血腫治療の臨床試験動向について調査・分析し、アジア/ヨーロッパ/アメリカ/中南米の主要国における治験件数、フェーズ別の治験件数、進捗状況別の治験件数、有望なスポンサー、有望な薬剤、治験関連の最新ニュース、主要企業分析、主要な治験プロファイル分析などの情報をご提供致します。
・血腫:主要地域別治験動向
・血腫:アジア市場
・血腫:ヨーロッパ市場
・血腫:アメリカ市場
・血腫:中南米市場
・血腫:中東・アフリカ市場
・血腫:段階(フェーズ)別治験件数
・血腫:進捗状況別の治験件数
・血腫:スポンサーの種類別治験件数
・血腫:有望なスポンサー
・血腫:有望な薬剤分析
・血腫:主要企業分析
【レポートの概要】

Hematoma Global Clinical Trials Review, H2, 2017

Summary

GlobalData’s clinical trial report, “Hematoma Global Clinical Trials Review, H2, 2017″ provides an overview of Hematoma clinical trials scenario. This report provides top line data relating to the clinical trials on Hematoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
GlobalData Clinical Trials Report Coverage 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Hematoma to Cardiovascular Clinical Trials 16
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Hematoma to Cardiovascular Clinical Trials 19
Clinical Trials by Phase in E7 Countries 20
Clinical Trials in E7 Countries by Trial Status 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Clinical Trials by End Point Status 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Hematoma Therapeutics Clinical Trials 29
Prominent Drugs 31
Clinical Trial Profile Snapshots 32
Appendix 47
Abbreviations 47
Definitions 47
Research Methodology 48
Secondary Research 48
About GlobalData 49
Contact Us 49
Source 49

List of Tables
Hematoma Therapeutics, Global, Clinical Trials by Region, 2017* 7
Hematoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
Hematoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
Hematoma Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2017* 11
Hematoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 12
Hematoma Therapeutics Clinical Trials, North America, Top Countries, 2017* 13
Hematoma Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 14
Hematoma Therapeutics Clinical Trials, Central and South America, Top Countries, 2017* 15
Proportion of Hematoma to Cardiovascular Clinical Trials, G7 Countries (%), 2017* 16
Hematoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
Hematoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
Proportion of Hematoma to Cardiovascular Clinical Trials, E7 Countries (%), 2017* 19
Hematoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20
Hematoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 21
Hematoma Therapeutics, Global, Clinical Trials by Phase, 2017* 22
Hematoma Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 23
Hematoma Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
Hematoma Therapeutics Clinical Trials, Global, by End Point Status, 2017* 25
Hematoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 26
Hematoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 27
Hematoma Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 28
Hematoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 30
Hematoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 31

List of Figures
Hematoma Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
Hematoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
Hematoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
Hematoma Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2017* 11
Hematoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 12
Hematoma Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 13
Hematoma Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017* 14
Proportion of Hematoma to Cardiovascular Clinical Trials, G7 Countries (%), 2017* 16
Hematoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
Hematoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
Proportion of Hematoma to Cardiovascular Clinical Trials, E7 Countries (%), 2017* 19
Hematoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20
Hematoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 21
Hematoma Therapeutics, Global, Clinical Trials by Phase (%), 2017* 22
Hematoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 23
Hematoma Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
Hematoma Therapeutics Clinical Trials, Global, by End Point Status, 2017* 25
Hematoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 26
Hematoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 27
Hematoma Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 28
Hematoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 29
Hematoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 31
GlobalData Methodology 48

【掲載企業】

URSAPHARM Arzneimittel GmbH
Nestle SA
Minapharm Pharmaceuticals & Chemical Industries
Elder Pharmaceuticals Ltd
C. H. Boehringer Sohn AG & Co KG
Bristol-Myers Squibb Company
Bayer AG
Baxter International Inc

【レポートのキーワード】

血腫、治験、臨床試験、治療薬

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 血腫:世界の治験レビュー(2017年下半期版)(Hematoma Global Clinical Trials Review, H2, 2017)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆